Peter M. Hecht - 06 May 2021 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)

Role: Chief Executive Officer, Director
Signature: /s/ Gary J. Simon, Attorney-in-Fact
Issuer symbol: CYCN
Transactions as of: 06 May 2021
Net transactions value: +$733,860
Form type: 4
Filing time: 10 May 2021, 08:45:24 UTC
Next filing: 07 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYCN	Common Stock	Purchase	$733,860	+302,000	+33%	$2.43	1,224,528	06 May 2021	Direct	F1
holding	CYCN	Common Stock						485	06 May 2021	The 2000 Trust for Alexis Mae Hecht	F2
holding	CYCN	Common Stock						485	06 May 2021	The 2000 Trust for Malcolm Paul Hecht	F2
holding	CYCN	Common Stock						485	06 May 2021	The 2000 Trust for Zoe Niovi Hecht	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.31 to $2.59, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
F2	These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose.

Content

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.31 to $2.59, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose.